1053 related articles for article (PubMed ID: 27455834)
1. Gd-nanoparticles functionalization with specific peptides for ß-amyloid plaques targeting.
Plissonneau M; Pansieri J; Heinrich-Balard L; Morfin JF; Stransky-Heilkron N; Rivory P; Mowat P; Dumoulin M; Cohen R; Allémann É; Tόth É; Saraiva MJ; Louis C; Tillement O; Forge V; Lux F; Marquette C
J Nanobiotechnology; 2016 Jul; 14(1):60. PubMed ID: 27455834
[TBL] [Abstract][Full Text] [Related]
2. In vivo SPECT imaging of amyloid-β deposition with radioiodinated imidazo[1,2-a]pyridine derivative DRM106 in a mouse model of Alzheimer's disease.
Chen CJ; Bando K; Ashino H; Taguchi K; Shiraishi H; Shima K; Fujimoto O; Kitamura C; Matsushima S; Uchida K; Nakahara Y; Kasahara H; Minamizawa T; Jiang C; Zhang MR; Ono M; Tokunaga M; Suhara T; Higuchi M; Yamada K; Ji B
J Nucl Med; 2015 Jan; 56(1):120-6. PubMed ID: 25476539
[TBL] [Abstract][Full Text] [Related]
3. Multimodal imaging Gd-nanoparticles functionalized with Pittsburgh compound B or a nanobody for amyloid plaques targeting.
Pansieri J; Plissonneau M; Stransky-Heilkron N; Dumoulin M; Heinrich-Balard L; Rivory P; Morfin JF; Toth E; Saraiva MJ; Allémann E; Tillement O; Forge V; Lux F; Marquette C
Nanomedicine (Lond); 2017 Jul; 12(14):1675-1687. PubMed ID: 28635419
[TBL] [Abstract][Full Text] [Related]
4. Transthyretin stabilization by iododiflunisal promotes amyloid-β peptide clearance, decreases its deposition, and ameliorates cognitive deficits in an Alzheimer's disease mouse model.
Ribeiro CA; Oliveira SM; Guido LF; Magalhães A; Valencia G; Arsequell G; Saraiva MJ; Cardoso I
J Alzheimers Dis; 2014; 39(2):357-70. PubMed ID: 24169237
[TBL] [Abstract][Full Text] [Related]
5. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
[TBL] [Abstract][Full Text] [Related]
6. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
[TBL] [Abstract][Full Text] [Related]
7. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques.
Poduslo JF; Curran GL; Peterson JA; McCormick DJ; Fauq AH; Khan MA; Wengenack TM
Biochemistry; 2004 May; 43(20):6064-75. PubMed ID: 15147190
[TBL] [Abstract][Full Text] [Related]
8. Transthyretin accelerates vascular Abeta deposition in a mouse model of Alzheimer's disease.
Wati H; Kawarabayashi T; Matsubara E; Kasai A; Hirasawa T; Kubota T; Harigaya Y; Shoji M; Maeda S
Brain Pathol; 2009 Jan; 19(1):48-57. PubMed ID: 18429966
[TBL] [Abstract][Full Text] [Related]
9. Astrocytosis precedes amyloid plaque deposition in Alzheimer APPswe transgenic mouse brain: a correlative positron emission tomography and in vitro imaging study.
Rodriguez-Vieitez E; Ni R; Gulyás B; Tóth M; Häggkvist J; Halldin C; Voytenko L; Marutle A; Nordberg A
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1119-32. PubMed ID: 25893384
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
11. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.
Kung MP; Skovronsky DM; Hou C; Zhuang ZP; Gur TL; Zhang B; Trojanowski JQ; Lee VM; Kung HF
J Mol Neurosci; 2003 Feb; 20(1):15-24. PubMed ID: 12663930
[TBL] [Abstract][Full Text] [Related]
12. Pre-plaque conformational changes in Alzheimer's disease-linked Aβ and APP.
Klementieva O; Willén K; Martinsson I; Israelsson B; Engdahl A; Cladera J; Uvdal P; Gouras GK
Nat Commun; 2017 Mar; 8():14726. PubMed ID: 28287086
[TBL] [Abstract][Full Text] [Related]
13. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.
Yang F; Lim GP; Begum AN; Ubeda OJ; Simmons MR; Ambegaokar SS; Chen PP; Kayed R; Glabe CG; Frautschy SA; Cole GM
J Biol Chem; 2005 Feb; 280(7):5892-901. PubMed ID: 15590663
[TBL] [Abstract][Full Text] [Related]
14. Validation by Magnetic Resonance Imaging of the Diagnostic Potential of a Heptapeptide-Functionalized Imaging Probe Targeted to Amyloid-β and Able to Cross the Blood-Brain Barrier.
André S; Ansciaux E; Saidi E; Larbanoix L; Stanicki D; Nonclercq D; Vander Elst L; Laurent S; Muller RN; Burtea C
J Alzheimers Dis; 2017; 60(4):1547-1565. PubMed ID: 29036827
[TBL] [Abstract][Full Text] [Related]
15.
Lerouge F; Ong E; Rositi H; Mpambani F; Berner LP; Bolbos R; Olivier C; Peyrin F; Apputukan VK; Monnereau C; Andraud C; Chaput F; Berthezène Y; Braun B; Jucker M; Åslund AK; Nyström S; Hammarström P; R Nilsson KP; Lindgren M; Wiart M; Chauveau F; Parola S
Nanomedicine (Lond); 2022 Dec; 17(29):2173-2187. PubMed ID: 36927004
[TBL] [Abstract][Full Text] [Related]
16. Styrylbenzoxazole derivatives for in vivo imaging of amyloid plaques in the brain.
Okamura N; Suemoto T; Shimadzu H; Suzuki M; Shiomitsu T; Akatsu H; Yamamoto T; Staufenbiel M; Yanai K; Arai H; Sasaki H; Kudo Y; Sawada T
J Neurosci; 2004 Mar; 24(10):2535-41. PubMed ID: 15014129
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal amyloid imaging in mouse brain with 11C-PIB: comparison of APP23, Tg2576, and APPswe-PS1dE9 mouse models of Alzheimer disease.
Snellman A; López-Picón FR; Rokka J; Salmona M; Forloni G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
J Nucl Med; 2013 Aug; 54(8):1434-41. PubMed ID: 23833271
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.
Poduslo JF; Wengenack TM; Curran GL; Wisniewski T; Sigurdsson EM; Macura SI; Borowski BJ; Jack CR
Neurobiol Dis; 2002 Nov; 11(2):315-29. PubMed ID: 12505424
[TBL] [Abstract][Full Text] [Related]
19. Gadolinium-complexed Aβ-binding contrast agents for MRI diagnosis of Alzheimer's Disease.
Matharu B; Spencer N; Howe F; Austen B
Neuropeptides; 2015 Oct; 53():63-70. PubMed ID: 26234669
[TBL] [Abstract][Full Text] [Related]
20. Pyroglutamation of amyloid-βx-42 (Aβx-42) followed by Aβ1-40 deposition underlies plaque polymorphism in progressing Alzheimer's disease pathology.
Michno W; Nyström S; Wehrli P; Lashley T; Brinkmalm G; Guerard L; Syvänen S; Sehlin D; Kaya I; Brinet D; Nilsson KPR; Hammarström P; Blennow K; Zetterberg H; Hanrieder J
J Biol Chem; 2019 Apr; 294(17):6719-6732. PubMed ID: 30814252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
